This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

IBio Adds To IBioModulator Portfolio And Product Pipeline

NEWARK, Del., March 13, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced notification from the U.S. Patent and Trademark Office that a new patent in the Company's iBioModulatorâ„¢ portfolio will issue on March 26, 2013. The new patent, number 8,404,252 entitled " Yersinia pestis Antigens, Vaccine Compositions and Related Methods," includes claims covering plague antigens fused to the Company's thermostable immunomodulator -- iBioModulator â„¢-- protein, as well as vaccine compositions and a method for producing a protective immune response to the antigen.  The invention was developed by scientists at the Fraunhofer USA Center for Molecular Biotechnology (FhCMB), iBio's research collaborator and is owned by iBio.

(Logo: )

Plague is considered a potential bioterrorism weapon.  There is no plague vaccine currently approved for use in the U.S.  Although killed whole-cell plague vaccines have been reported to protect against bubonic plague in animal models, such vaccines were not effective against pneumonic plague.  By contrast, data previously published in the peer-reviewed scientific journal, Vaccine, demonstrated that a recombinant plague vaccine incorporating the iBioModulator protein, and produced via the iBioLaunchâ„¢ platform in green plants, provided  full protection of non-human primates against aerosolized Y. pestis (pneumonic plague).

An immunomodulator is a substance that alters the immune response.  The iBioModulator platform has been shown in animal models to significantly modify the immune response to a vaccine in two important ways. It increased the strength of the initial immune response to a vaccine antigen (as measured by antibody titer).  It also extended the duration of the immune response. These results demonstrate that the use of the iBioModulator platform may lower vaccine antigen requirements and enable fewer doses to establish prolonged immunity. The ability to improve immune response and provide longer-term protection without the necessity of booster inoculations would add significant value to a vaccine by reducing the overall costs and logistical difficulties of its use while effectively reaching a higher proportion of the target population.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs